News

The latest press releases, publications, and events for Innoviva Specialty Therapeutics

Filter by:

All News Press Releases Events

04.28.2016

Absorption, distribution, metabolism and elimination of 14C-ETX0914, a novel inhibitor of bacterial type-II topoisomerases in rodents

Read More

03.08.2016

Effect of Susceptibility Testing Conditions on the In Vitro Antibacterial Activity of ETX0914

Read More

12.31.2015

Multidrug-Resistant Neisseria gonorrhoeae Isolates from Nanjing, China, Are Sensitive to Killing by a Novel DNA Gyrase Inhibitor, ETX0914 (AZD0914)

Read More

12.10.2015

Genetic Resistance Determinants, In Vitro Time-Kill Curve Analysis and Pharmacodynamic Functions for the Novel Topoisomerase II Inhibitor ETX0914 (AZD0914) in Neisseria gonorrhoeae

Read More

09.18.2015

In Vitro Activity of AZD0914, a Novel Bacterial DNA Gyrase/Topoisomerase IV Inhibitor, against Clinically Relevant Gram-Positive and Fastidious Gram-Negative Pathogens

Read More

09.06.2015

Update on Treatment Options for Gonococcal Infections

Read More

08.14.2015

High In Vitro Susceptibility to the Novel Spiropyrimidinetrione ETX0914 (AZD0914) among 873 Contemporary Clinical Neisseria gonorrhoeae Isolates from 21 European Countries from 2012 to 2014

Read More

07.14.2015

Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases

Read More

07.09.2015

Discovery of Novel DNA Gyrase Inhibiting Spiropyrimidinetriones: Benzisoxazole Fusion with N-Linked Oxazolidinone Substituents Leading to a Clinical Candidate (ETX0914)

Read More

05.14.2015

In Vitro Antibacterial Activity of AZD0914 against Human Mycoplasmas and Ureaplasmas

Read More